JLS Fund

JLS Fund is one of the investment funds that is moving the psychedelic space forward. It invests in early-stage ‘plant medicine’ start-ups.

JLS Fund

From its website “JLS was formed to invest in the exciting intersection of science, technology and neurology, leveraging the enormous potential of plant-based and psychedelic medicines to heal illness and enhance wellness. We focus on the development of drugs for intractable mental and physical conditions and the enabling technology and tools that can accelerate and enhance the delivery of those therapies.”

The company’s Fund one is deploying $50 million within the next 3 years.

You can find their July 2021 update here.

Investments

(some may only be advisory roles, this isn’t specified)

• Cybin
• MindMed
• Gilgamesh – confirmed investment
• Diamond Therapeutics
• Myco Systemics
• Tactogen
• Mindleap Health
• atai Life Sciences – confirmed investment
• Universal Ibogaine
• Good Cap
• Gwella
• Lucid News
• Orthogonal
• DoubleBlind
• Wesana – confirmed investment
• Tripp – confirmed investment
• Psilera – confirmed investment
• Tabula Rasa – confirmed investment
• Fluence – confirmed investment

Key Staff

• Lindsay Hoover – Managing partner
• Jeffrey Siegel – Managing partner & investor relations
• Simeon Schnapper – Managing partner
• Abhi Vase – Advisor
• Michael Gruber – Advisor
• Walter Greenleaf – Advisor
• Lorne Gertner – Advisor

Media

• How an Investor Evaluates Five Leading Psychedelic Therapy Companies (Lucid News, May 2021)
• Interview with Simeon Schnapper, Managing Partner of JLS (Psilocybin Alpha, September 2020)